

Special Issue

Breast Cancer: Mechanisms of Development and Progression and Novel Approaches to Clinical Management

Message from the Guest Editors

Breast cancer is a major cause of morbidity and mortality among women worldwide. A significant progress has been made in our understanding of the biology of breast cancer that has served as a foundation for the development of clinically effective diagnostic, prevention, and treatment strategies. While in early-stage breast cancer, excellent outcomes are observed, the metastatic, recurrent, and drug-resistant disease still confers an unacceptably poor prognosis. Certain subtypes of this malignancy, such as its most aggressive triple-negative subtype, lack predictive and treatment biomarkers, which contributes to the relatively poor oncologic outcomes. The significant heterogeneity of breast cancer mandates a nuanced understanding and management that requires further research efforts. This issue discusses mechanisms of breast cancer development and progression, as well as presents recent preclinical studies on novel approaches in treatment of this condition.

Guest Editors

Dr. Armen Parsyan

General Surgeon and Breast Surgical Oncologist, Clinician-Scientist Assistant Professor, Departments of Surgery and Oncology, St Joseph's Health Care and London Health Sciences Centre, London Regional Cancer Program, Schulich School of Medicine & Dentistry, Western University London, ON

Dr. Vasudeva Bhat

Anatomy and Cell Biology, University of Western Ontario, London, ON, Canada

Deadline for manuscript submissions

closed (31 August 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/65685

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).